# uniQure N.V. (QURE) insider trading

> In the 12 months to Nov 22, 2026, 6 QURE insiders reported open-market sales of $17.9M across 14 filings; no open-market purchases were filed.

Canonical: https://massive.com/quote/qure/insider-trading
Latest filing: 2026-11-10 (last 12 months; source: SEC EDGAR)
Source: Massive (https://massive.com/docs/llms.txt)

## Summary

| Measure | Value | Detail |
| --- | --- | --- |
| Open-market sales | $17.9M | 14 filings · 6 insiders |
| Open-market purchases | $0 | 0 filings |
| Pre-arranged sales (10b5-1) | 14 of 14 | All $17.9M sold was pre-arranged |

## Open-market trades by insider

| Insider | Role | Sold | Bought | Filings | Pre-arranged (10b5-1) | Last filed |
| --- | --- | --- | --- | --- | --- | --- |
| Matthew C. Kapusta | CEO, Managing Director | $12.1M | — | 3 | 100% of sales | 2026-07-07 |
| Walid Abi-Saab | Chief Medical Officer | $2.5M | — | 2 | 100% of sales | 2026-07-02 |
| Jack Kaye | Director | $1.5M | — | 4 | 100% of sales | 2026-07-02 |
| Robert Gut | Director | $827.2K | — | 2 | 100% of sales | 2026-06-12 |
| Madhavan Balachandran | Director | $805.0K | — | 2 | 100% of sales | 2026-06-22 |
| David D. Meek | Director | $193.0K | — | 1 | 100% of sales | 2026-11-10 |

## Open-market trades by filing

14 filings in the last 12 months, newest first.

| Filed | Traded | Insider | Role | Type | Shares | Value | Held after | Filing |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| 2026-11-10 | 2026-11-06 | David D. Meek | Director | Sale (10b5-1) | 9,080 ordinary shares | $193.0K | 30,667 | — |
| 2026-07-07 | 2026-07-02 | Matthew C. Kapusta | CEO, Managing Director | Sale (10b5-1) | 21,082 ordinary shares | $952.1K | 526,827 | — |
| 2026-07-02 | 2026-06-30 | Jack Kaye | Director | Sale (10b5-1) | 21,167 ordinary shares | $983.0K | 25,996 | — |
| 2026-07-02 | 2026-06-30 | Walid Abi-Saab | Chief Medical Officer | Sale (10b5-1) | 30,000 ordinary shares | $1.4M | 168,235 | — |
| 2026-06-26 | 2026-06-24 | Matthew C. Kapusta | CEO, Managing Director | Sale (10b5-1) | 35,412 ordinary shares | $1.8M | 519,227 | — |
| 2026-06-22 | 2026-06-17 | Jack Kaye | Director | Sale (10b5-1) | 5,295 ordinary shares | $225.4K | 25,996 | — |
| 2026-06-22 | 2026-06-17 | Madhavan Balachandran | Director | Sale (10b5-1) | 11,685 ordinary shares | $526.5K | 43,254 | — |
| 2026-06-22 | 2026-06-17 | Matthew C. Kapusta | CEO, Managing Director | Sale (10b5-1) | 206,100 ordinary shares | $9.4M | 558,810 | — |
| 2026-06-17 | 2026-06-15 | Madhavan Balachandran | Director | Sale (10b5-1) | 10,000 ordinary shares | $278.5K | 43,254 | — |
| 2026-06-12 | 2026-06-10 | Robert Gut | Director | Sale (10b5-1) | 7,552 ordinary shares | $196.7K | 32,342 | — |
| 2026-06-05 | 2026-06-03 | Jack Kaye | Director | Sale (10b5-1) | 2,645 ordinary shares | $79.4K | 20,439 | — |
| 2026-05-12 | 2026-05-08 | Walid Abi-Saab | Chief Medical Officer | Sale (10b5-1) | 45,000 ordinary shares | $1.1M | 169,669 | — |
| 2026-01-14 | 2026-01-12 | Robert Gut | Director | Sale (10b5-1) | 25,613 ordinary shares | $630.5K | 32,342 | — |
| 2026-01-12 | 2026-01-09 | Jack Kaye | Director | Sale (10b5-1) | 6,390 ordinary shares | $174.3K | 20,439 | — |

## Other insider activity (not market trades)

- Option exercises: 17 records
- Tax withholding (sold to cover): 20 records
- Grants and awards: 13 records

Reported on Form 4 but not purchases or sales in the market, so not counted in the totals above.

## How to read this page

- **Open-market purchase or sale**: A buy or sell of the company's stock at market price. Grants, option exercises, shares withheld for tax, gifts and employee stock plan purchases are listed separately and not counted.
- **Pre-arranged (10b5-1)**: The insider marked the filing as made under a trading plan set up in advance (SEC Rule 10b5-1). The mark covers the whole filing, and an unmarked filing may still be under a plan.
- **Filing date**: Insiders have two business days to report a trade. Totals and the chart use the filing date, when the trade became public.

## FAQ

### Has uniQure N.V.'s CEO sold stock?

Yes. Matthew C. Kapusta (CEO) sold 262,594 shares ($12.1M) between Jun 2026 and Jul 2026, all under a pre-arranged 10b5-1 plan.

### How current is QURE’s insider data?

These are QURE Form 4 filings from the last year, refreshed daily. The Massive Form 4 API has the full, continuously updated record.

### What counts as an open-market buy or sell?

Only purchases and sales at the market price. Option exercises, grants, gifts, and shares withheld for taxes are reported on Form 4 but are left out of the buy and sell totals.

## Live data

This page joins two Massive endpoints: Form 4 filings and daily prices. The QURE Form 4 request:

- `GET https://api.massive.com/stocks/filings/vX/form-4?tickers=QURE&filing_date.gte=2025-11-22&sort=filing_date.desc&limit=500`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [uniQure N.V. (QURE) stock price](https://massive.com/quote/qure.md)
- [Recent insider trading](https://massive.com/quote/insider-trading.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
